Pembrolizumab biosimilar - Prestige Biopharma
Alternative Names: PBP-2102Latest Information Update: 22 Feb 2022
At a glance
- Originator Prestige BioPharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Malignant melanoma
Most Recent Events
- 08 Feb 2022 Early research in Malignant melanoma (Metastatic disease, Inoperable/Unresectable) in Singapore (Parenteral) (Prestige Biopharma pipeline, February 2022)